Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

Fairview University Medical Center

Status: Completed

Conditions: Leukemia, Nonlymphocytic, Acute; Leukemia, Lymphocytic, Acute; Fanconi's Anemia; Myelodysplastic Syndromes

Treatments: Procedure: Allogeneic Bone Marrow Transplantation; Drug: cyclophosphamide

Study type: Interventional

Funder types: Other

Identifiers

NCT00005892

UMN-MT-1985-01

199/15100

UMN-MT-8501

Details and patient eligibility

About

OBJECTIVES:

I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with myelodysplastic syndrome and acute leukemia related to Fanconi's anemia.

Full description

PROTOCOL OUTLINE:

Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.

Sex: All

Ages: Under 54 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Diagnosis of Fanconi's anemia with the family history and typical phenotype including: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility
• Evidence of Fanconi's myelodysplastic syndrome Bone marrow dysplasia of all 3 marrow cell lines AND Clonal cytogenetic abnormalities demonstrable in marrow cells
• First complete remission following therapy for Fanconi's acute leukemia allowed
• Must have related histocompatible donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow